KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Invested Capital (2016 - 2026)

TherapeuticsMD filings provide 17 years of Invested Capital readings, the most recent being $27.0 million for Q1 2026.

  • On a quarterly basis, Invested Capital rose 0.87% to $27.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $27.0 million, a 0.87% increase, with the full-year FY2025 number at $26.9 million, down 1.8% from a year prior.
  • Invested Capital hit $27.0 million in Q1 2026 for TherapeuticsMD, roughly flat from $26.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $64.7 million in Q2 2022 to a low of $26.7 million in Q1 2025.
  • Median Invested Capital over the past 5 years was $28.1 million (2023), compared with a mean of $33.8 million.
  • The widest YoY moves for Invested Capital: up 265.62% in 2022, down 64.31% in 2022.
  • TherapeuticsMD's Invested Capital stood at $35.1 million in 2022, then fell by 16.66% to $29.3 million in 2023, then fell by 6.55% to $27.4 million in 2024, then dropped by 1.8% to $26.9 million in 2025, then rose by 0.36% to $27.0 million in 2026.
  • The last three reported values for Invested Capital were $27.0 million (Q1 2026), $26.9 million (Q4 2025), and $27.4 million (Q3 2025) per Business Quant data.